GSK2606414 enhanced the sensitivity of CD34+ primary AML cells and significantly enhanced the BIX-01294-induced cell apoptosis (24.79 ± 1.77% for BIX-01294 alone and 60.38 ± 3.39% for BIX-01294 plus GSK2606414; P < 0.0001; Fig. 3a, left panel). The gene discussed is CD34; the disease is acute myeloid leukemia.